Immune-mediated endocrine adverse events during treatment with immune checkpoint inhibitors: a clinical case of nivolumab-induced thyroiditis
- Authors: Zhurtova I.B.1, Elgarova L.V1, Gubachikova A.M1
-
Affiliations:
- Kabardino-Balkarian State University n.a. Kh.M. Berbekov
- Issue: Vol 29, No 7 (2022)
- Pages: 90-94
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321034
- DOI: https://doi.org/10.18565/pharmateca.2022.7.90-94
- ID: 321034
Cite item
Open Access
Access granted
Abstract
Background. Nivolumab is an anti-PD1 (programmed cell death protein 1) monoclonal antibody approved for the treatment of malignant melanoma, advanced non-small cell lung cancer, and advanced renal cell carcinoma. Cases of endocrinopathies including hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, diabetes mellitus, and diabetic ketoacidosis against thebackground of nivolumab therapy have been reported. The frequency and risk of developing such adverse events after the use of regimens of immune checkpoint inhibitors are unknown. Patients receiving combination therapy are at increased risk of thyroid dysfunction and hypophysitis. Description of the clinical case. The article discusses the mechanisms of development of adverse events in the application of nivolumab on the example of a clinical case of thyroiditis in a 42-year-old man with metastatic melanoma. Conclusion. Immunotherapy is one of the methods of treatment of malignant neoplasms in oncology. Due to the wider use of immunotherapy, the question about the tactics of managing immune-mediated adverse events arises.
Full Text
About the authors
Inessa B. Zhurtova
Kabardino-Balkarian State University n.a. Kh.M. Berbekov
Email: zhin07@mail.ru
Dr. Sci. (Med.), Professor at the Department of Faculty Therapy Nalchik, Russia
L. V Elgarova
Kabardino-Balkarian State University n.a. Kh.M. BerbekovFaculty of Medicine Nalchik, Russia
A. M Gubachikova
Kabardino-Balkarian State University n.a. Kh.M. BerbekovFaculty of Medicine Nalchik, Russia
References
- Ключагина Ю.И., Соколова З.А., Барышникова М.А. Роль рецептора PD1 и его лигандов PDL1 и PDL2 в иммунотерапии опухолей. Онкопедиатрия. 2017;4(1):49-55. doi: 10.15690/onco.v4i1.1684.
- Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609.
- Deeks E.D. Nivolumab: a review of its use in patients with malignant melanoma. Drugs. 2014;74(11):1233-39. doi: 10.1007/s40265-014-0234-4.
- Reichert J.M. Antibodies to watch in 2015. MAbs. 2015;7(1):1-8. doi: 10.4161/19420862.2015. 988944.
- Robert C, Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. doi: 10.1056/NEJMoa1412082.
- Min L., Vaidya A., Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164(2):303-7. doi: 10.1530/EJE-10-0833.
- Rajan A., Kim C., Heery C.R., Guha U., Gulley J.L. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother. 2016;12(9):2219-31. doi: 10.1080/21645515.2016.1175694.
- Регистрационное удостоверение. Ниволумаб (Опдиво). [Registration certificate. Nivolumab (Opdivo). (In Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7560c36ae8e8-4092-8c46-e85f14a121e4&t= (дата обращения / access date: 13.01.2017).
- Тер-Ованесов М.Д., Кукош М.Ю., Пименов И.В. и др. Ниволумаб - ингибитор рецептора программированной смерти-1: роль в лечении злокачественных опухолей. Медицинский алфавит. 2017;1(16):23-28.
- Weber J.S., D’Angelo S.P, Minor D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8.
- Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30. doi: 10.1056/NEJMoa1412082.
- Larkin J., Chiarion-Sileni V., Gonzalez R., et al.Combined Nivolumab and ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2012;373(1):23-34. doi: 10.1026/NEJMoa1504030.
- Nishimura H., Nose M., Hiai H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141-151. doi: 10.1016/S1074-7613(00)80089-8.
- Dong H., Strome S.E., Salomao D.R., et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. doi: 10.1038/nm730.
- Byun D.J., Wolchok J.D., Rosenberg L.M., Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13(4):192-207. doi: 10.1038/nrendo.2016.205.
- Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., et al. incidence of Endocrine Dysfunction Following the Use of Different immune Checkpoint inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(2):173-82. doi: 10.1001/jamaoncol.2017.3064.
- Yamauchi i., Sakane Y., Fukuda Y., et al. Clinical features of nivolumab-induced thyroiditis: a case series study. Thyroid. 2017;27(7):894-901. doi: 10.1089/thy.2016.0562.
- Larkin J., Chiarion-Sileni V., Gonzalez R., et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1 ):23-34. doi: 10.1026/NEJMoa1504030.
Supplementary files
